Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3084899rdf:typepubmed:Citationlld:pubmed
pubmed-article:3084899lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:3084899lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:3084899lifeskim:mentionsumls-concept:C0039044lld:lifeskim
pubmed-article:3084899lifeskim:mentionsumls-concept:C1705480lld:lifeskim
pubmed-article:3084899lifeskim:mentionsumls-concept:C0027893lld:lifeskim
pubmed-article:3084899lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:3084899lifeskim:mentionsumls-concept:C1521801lld:lifeskim
pubmed-article:3084899pubmed:issue20lld:pubmed
pubmed-article:3084899pubmed:dateCreated1986-6-25lld:pubmed
pubmed-article:3084899pubmed:abstractTextThe haemodynamic effects of intracerebroventricular (i.c.v.) administration of neuropeptide Y (NPY) in urethane-anaesthetized rats were studied. In Sprague-Dawley rats, NPY increased both blood pressure and heart rate in a dose-dependent manner. This response was unaffected by removal of the adrenal medullae or pretreatment with a specific vasopressin antagonist (180 ng/kg i.v.), but was abolished by phenoxybenzamine (1mg/kg i.v.). After pretreatment with propranolol (1mg/kg i.v.), the tachycardia was inhibited and the pressor response was of shorter duration than in controls. In 6-hydroxydopamine treated rats (two doses of 250 micrograms i.c.v., three days apart), NPY still elicited a pressor response and tachycardia, which were significantly higher than controls 15 minutes after the injection. Plasma levels of vasopressin were not altered by i.c.v. administration of NPY. However, in Brattleboro rats the peptide had no haemodynamic effects. Our results suggest that activation of sympathetic nervous system but not release of vasopressin or adrenal catecholamines into the bloodstream mediates the cardiovascular response to NPY. Central vasopressin pathways however may be involved.lld:pubmed
pubmed-article:3084899pubmed:languageenglld:pubmed
pubmed-article:3084899pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084899pubmed:citationSubsetIMlld:pubmed
pubmed-article:3084899pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084899pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084899pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084899pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084899pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084899pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084899pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084899pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3084899pubmed:statusMEDLINElld:pubmed
pubmed-article:3084899pubmed:monthMaylld:pubmed
pubmed-article:3084899pubmed:issn0024-3205lld:pubmed
pubmed-article:3084899pubmed:authorpubmed-author:VallejoMMlld:pubmed
pubmed-article:3084899pubmed:authorpubmed-author:LightmanS LSLlld:pubmed
pubmed-article:3084899pubmed:issnTypePrintlld:pubmed
pubmed-article:3084899pubmed:day19lld:pubmed
pubmed-article:3084899pubmed:volume38lld:pubmed
pubmed-article:3084899pubmed:ownerNLMlld:pubmed
pubmed-article:3084899pubmed:authorsCompleteYlld:pubmed
pubmed-article:3084899pubmed:pagination1859-66lld:pubmed
pubmed-article:3084899pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:meshHeadingpubmed-meshheading:3084899-...lld:pubmed
pubmed-article:3084899pubmed:year1986lld:pubmed
pubmed-article:3084899pubmed:articleTitlePressor effect of centrally administered neuropeptide Y in rats: role of sympathetic nervous system and vasopressin.lld:pubmed
pubmed-article:3084899pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3084899pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3084899lld:pubmed